|

Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

RECRUITINGSponsored by Assistance Publique - Hôpitaux de Paris
Actively Recruiting
SponsorAssistance Publique - Hôpitaux de Paris
Started2023-03-13
Est. completion2030-03
Eligibility
Age16 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05534347

Summary

The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

Eligibility

Age: 16 Years+Healthy volunteers accepted
Inclusion Criteria:

* Greater than or equal to 16 years-old
* Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital
* No-opposition to the research
* Patient with health insurance
* Mastery of the French language

Exclusion Criteria:

* Patient under curatorship or guardianship
* Patient receiving french state medical aid

Conditions2

ArthritisJuvenile Idiopathic Arthritis (JIA)

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.